Skip to main content

Economics

Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Akhil Sood MD, MS
@AkhilSoodMD
What drives differences in joint procedures? Abstract 2717 found that joint procedures • Varied more btwn hospitals (13.97-32.23) vs w/i (1.24-1.3) • Ultrasound tied to higher prices small(1.07), large joint(1.57) • Prices differed by payer and rurality #ACR26 @rheumnow
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 Annual Meeting is sponsored by Eli Lilly and Company . All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb and Tonix. All coverage content is independently selected by RheumNow and its faculty.

ACR Responds to Final Medicare Payment Rule from CMS

ACR

The American College of Rheumatology (ACR) today issued the following statement in response to the final Medicare Physician Fee Schedule (MPFS) for calendar year 2027 (CY27) from the Centers for Medicare & Medicaid Services (CMS).

Autologous HCT in Severe Systemic Sclerosis

Jack Cush, MD

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early severe systemic sclerosis.

Dr. John Cush
@RheumNow
Using Global Burden of Disease study data, an economic evaluation of 204 countries & territories, osteoarthritis & Alzheimers/dementias had highest health burden, but largest economic losses observed for combinations involving osteoarthritis, particularly osteoarthritis and https://t.co/0JgRgJAWy7

Treat-to-Target has Excellent 10-Year Outcomes in RA

MedPage Today

Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said.

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 

Can DMARD Doses Be Safely Reduced for RA Patients?

MedPage Today

Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean researchers said.

×